Catherine M. Tangen

63.4k total citations · 12 hit papers
254 papers, 38.7k citations indexed

About

Catherine M. Tangen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Catherine M. Tangen has authored 254 papers receiving a total of 38.7k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Pulmonary and Respiratory Medicine, 58 papers in Oncology and 53 papers in Surgery. Recurrent topics in Catherine M. Tangen's work include Prostate Cancer Treatment and Research (135 papers), Prostate Cancer Diagnosis and Treatment (87 papers) and Bladder and Urothelial Cancer Treatments (39 papers). Catherine M. Tangen is often cited by papers focused on Prostate Cancer Treatment and Research (135 papers), Prostate Cancer Diagnosis and Treatment (87 papers) and Bladder and Urothelial Cancer Treatments (39 papers). Catherine M. Tangen collaborates with scholars based in United States, Canada and Australia. Catherine M. Tangen's co-authors include Jeremy Walston, Mary Ann McBurnie, Russell P. Tracy, John S. Gottdiener, Linda P. Fried, Calvin H. Hirsch, Anne B. Newman, Willem J. Kop, Gregory L. Burke and Teresa E. Seeman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Catherine M. Tangen

246 papers receiving 37.7k citations

Hit Papers

Frailty in Older Adults: ... 1993 2026 2004 2015 2001 2004 2003 2003 2004 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Frailty in Older Adults: Evidence for a Phenotype
    2001 16.9k citations Catherine M. Tangen et al. profile →
  2. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
    2004 2.9k citations Catherine M. Tangen, Maha Hussain et al. New England Journal of Medicine profile →
  3. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
    2003 1.8k citations H. Barton Grossman, Ronald B. Natale et al. New England Journal of Medicine profile →
  4. The Influence of Finasteride on the Development of Prostate Cancer
    2003 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. New England Journal of Medicine profile →
  5. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
    2004 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. New England Journal of Medicine profile →
  6. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
    2007 864 citations Ian M. Thompson, Edith Canby‐Hagino et al. profile →
  7. Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
    2009 826 citations Ian M. Thompson, Catherine M. Tangen et al. profile →
  8. Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer
    2006 664 citations Ian M. Thompson, Catherine M. Tangen et al. profile →
  9. Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
    2006 658 citations Ian M. Thompson, Donna P. Ankerst et al. JNCI Journal of the National Cancer Institute profile →
  10. Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
    2007 631 citations Edith Canby‐Hagino, Jeffrey D. Forman et al. profile →
  11. A Southwest Oncology Group study
    1993 591 citations Catherine M. Tangen et al. profile →
  12. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
    2021 170 citations Catherine M. Tangen, Ian M. Thompson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine M. Tangen United States 57 14.5k 11.0k 9.3k 6.7k 5.1k 254 38.7k
Gregory L. Burke United States 102 7.6k 0.5× 11.3k 1.0× 13.6k 1.5× 8.2k 1.2× 1.2k 0.2× 347 57.6k
Stefan D. Anker Germany 117 7.5k 0.5× 4.5k 0.4× 13.0k 1.4× 7.4k 1.1× 1.5k 0.3× 734 56.7k
Harvey Jay Cohen United States 75 2.7k 0.2× 7.0k 0.6× 5.2k 0.6× 1.5k 0.2× 5.7k 1.1× 370 23.1k
Glenn M. Chertow United States 121 9.9k 0.7× 2.0k 0.2× 5.5k 0.6× 12.2k 1.8× 1.6k 0.3× 814 69.5k
Bruno H. Stricker Netherlands 90 4.1k 0.3× 1.8k 0.2× 3.7k 0.4× 3.7k 0.5× 2.2k 0.4× 571 30.4k
John S. Gottdiener United States 85 4.2k 0.3× 11.7k 1.1× 10.7k 1.1× 6.1k 0.9× 1.0k 0.2× 306 44.4k
Jeremy Walston United States 82 2.4k 0.2× 24.3k 2.2× 22.8k 2.4× 4.9k 0.7× 1.3k 0.2× 331 45.4k
Bruce M. Psaty United States 110 4.4k 0.3× 1.5k 0.1× 5.2k 0.6× 6.6k 1.0× 1.2k 0.2× 642 46.3k
Kamyar Kalantar‐Zadeh United States 121 6.1k 0.4× 1.2k 0.1× 11.4k 1.2× 8.5k 1.3× 1.2k 0.2× 916 52.3k
Charles L. Loprinzi United States 91 5.2k 0.4× 1.4k 0.1× 8.2k 0.9× 3.4k 0.5× 15.5k 3.1× 531 33.3k

Countries citing papers authored by Catherine M. Tangen

Since Specialization
Citations

This map shows the geographic impact of Catherine M. Tangen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine M. Tangen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine M. Tangen more than expected).

Fields of papers citing papers by Catherine M. Tangen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine M. Tangen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine M. Tangen. The network helps show where Catherine M. Tangen may publish in the future.

Co-authorship network of co-authors of Catherine M. Tangen

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine M. Tangen. A scholar is included among the top collaborators of Catherine M. Tangen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine M. Tangen. Catherine M. Tangen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Hyung L., Catherine M. Tangen, Ulka N. Vaishampayan, et al.. (2024). SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars and Original Investigations. 42. S4–S4. 2 indexed citations
2.
3.
Gebrael, Georges, Yeonjung Jo, Umang Swami, et al.. (2024). Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer. JAMA Network Open. 7(7). e2419966–e2419966. 4 indexed citations
4.
Black, Peter C., Catherine M. Tangen, Parminder Singh, et al.. (2023). Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605. European Urology. 84(6). 536–544. 48 indexed citations
5.
Halabi, Susan, Larysa Rydzewska, Peter J. Godolphin, et al.. (2023). 1837P Assessing PSA. Annals of Oncology. 34. S994–S995. 1 indexed citations
6.
7.
Xu, Jiayi, Kristin A. Guertin, Nathan Gaddis, et al.. (2022). Change in plasma α-tocopherol associations with attenuated pulmonary function decline and with CYP4F2 missense variation. American Journal of Clinical Nutrition. 115(4). 1205–1216. 3 indexed citations
8.
Schenk, Jeannette M., Cathee Till, Marian L. Neuhouser, et al.. (2022). Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiology Biomarkers & Prevention. 31(11). 2063–2069. 1 indexed citations
9.
Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2021). A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research. 27(9). 2435–2441. 58 indexed citations
10.
Hurwitz, Lauren M., İbrahim Kulaç, Berrak Gümüşkaya, et al.. (2020). Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research. 13(10). 853–862. 7 indexed citations
11.
Torkko, Kathleen C., Cathee Till, Catherine M. Tangen, et al.. (2020). Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Cancer Prevention Research. 13(6). 521–530. 4 indexed citations
12.
Tangen, Catherine M., Jeannette M. Schenk, Cathee Till, et al.. (2019). Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. Cancer Epidemiology. 63. 101619–101619. 4 indexed citations
13.
Dai, James Y., Michael LeBlanc, Phyllis J. Goodman, et al.. (2018). Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer Prevention Research. 12(2). 113–120. 2 indexed citations
14.
Chan, June M., Amy K. Darke, Kathryn L. Penney, et al.. (2016). Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers & Prevention. 25(7). 1050–1058. 47 indexed citations
15.
Marshall, James R., Catherine M. Tangen, Wael Sakr, et al.. (2011). Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917. Cancer Prevention Research. 4(11). 1761–1769. 83 indexed citations
16.
Redman, Mary W., Catherine M. Tangen, Phyllis J. Goodman, et al.. (2008). Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach. Cancer Prevention Research. 1(3). 174–181. 140 indexed citations
17.
Swanson, Gregory P., Michael A. Hussey, Catherine M. Tangen, et al.. (2007). Predominant Treatment Failure in Postprostatectomy Patients Is Local: Analysis of Patterns of Treatment Failure in SWOG 8794. Journal of Clinical Oncology. 25(16). 2225–2229. 198 indexed citations
18.
Thompson, Ian M., Chi Chen, Donna P. Ankerst, et al.. (2006). Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer. JNCI Journal of the National Cancer Institute. 98(16). 1128–1133. 217 indexed citations
19.
Beer, Tomasz M., Catherine M. Tangen, Craig R. Nichols, et al.. (2006). Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 106(12). 2624–2629. 23 indexed citations
20.
Grossman, H. Barton, Ronald B. Natale, Catherine M. Tangen, et al.. (2003). Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. New England Journal of Medicine. 349(9). 859–866. 1834 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregory L. Burke Breakdown of academic impact, for papers by Stefan D. Anker Breakdown of academic impact, for papers by Harvey Jay Cohen Breakdown of academic impact, for papers by Glenn M. Chertow Breakdown of academic impact, for papers by Bruno H. Stricker Breakdown of academic impact, for papers by John S. Gottdiener Breakdown of academic impact, for papers by Jeremy Walston Breakdown of academic impact, for papers by Bruce M. Psaty Breakdown of academic impact, for papers by Kamyar Kalantar‐Zadeh Breakdown of academic impact, for papers by Charles L. Loprinzi
Rankless by CCL
2026